Well after months and months of tough negotiations, weeding out the lowest bidders and not rushing to sign anything, I'm looking to see what good deal DD has got for us. I've just been looking at MTFB and annoyed that their MC is currently more than 50% higher than ours ... this should change by the end of September. ATB, L4J
I reckon it's simply that the market now wants more details fleshed out about the new investment terms. How favourable might they be? I'm not massively keen on a convertible loan component although the higher the conversion price the better. If they've bought @ 150p like Simbec are that will be very bullish indeed for the shares sitting around 43p!
I wouldn't say that. There was a 60k buy at the end of the day.
Well the excitement seems to have petered out. Will we track back to 37p now??
Link below is to an article in The NewEconomy by Dimitri Dimitriou which appeared yesterday but obviously was penned before the last couple of RNS's. Gives a good overview of the Company and a little bit more detail on what Dr. Gilles Guichard has been up to with the Urelix project. http://www.theneweconomy.com/business/immupharma-sets-its-sights-high-for-drug-development
That link SK posted earlier in the week - the article highlights the difference between IMM's approach and those targeting B cell treatments. http://www.proactiveinvestors.co.uk/companies/news/62599/can-immupharma-provide-the-antidote-to-me-too-failures--73143.html
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.